Logo image of RDHL

REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RDHL - US7574683014 - ADR

1.24 USD
-0.03 (-2.36%)
Last: 1/13/2026, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to RDHL. RDHL was compared to 190 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RDHL have multiple concerns. While showing a medium growth rate, RDHL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RDHL has reported negative net income.
  • In the past year RDHL has reported a negative cash flow from operations.
  • In the past 5 years RDHL reported 4 times negative net income.
  • RDHL had a negative operating cash flow in each of the past 5 years.
RDHL Yearly Net Income VS EBIT VS OCF VS FCFRDHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of RDHL (-45.00%) is worse than 60.00% of its industry peers.
Industry RankSector Rank
ROA -45%
ROE N/A
ROIC N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RDHL Yearly ROA, ROE, ROICRDHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 60.31%, RDHL is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
  • RDHL's Gross Margin has been stable in the last couple of years.
  • RDHL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
RDHL Yearly Profit, Operating, Gross MarginsRDHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

  • RDHL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RDHL has been increased compared to 1 year ago.
  • Compared to 5 years ago, RDHL has more shares outstanding
  • Compared to 1 year ago, RDHL has an improved debt to assets ratio.
RDHL Yearly Shares OutstandingRDHL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
RDHL Yearly Total Debt VS Total AssetsRDHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -34.57, we must say that RDHL is in the distress zone and has some risk of bankruptcy.
  • RDHL has a worse Altman-Z score (-34.57) than 90.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -34.57
ROIC/WACCN/A
WACC8.39%
RDHL Yearly LT Debt VS Equity VS FCFRDHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

  • A Current Ratio of 0.56 indicates that RDHL may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.56, RDHL is doing worse than 91.58% of the companies in the same industry.
  • A Quick Ratio of 0.42 indicates that RDHL may have some problems paying its short term obligations.
  • RDHL's Quick ratio of 0.42 is on the low side compared to the rest of the industry. RDHL is outperformed by 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.42
RDHL Yearly Current Assets VS Current LiabilitesRDHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

  • RDHL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.30%.
  • Looking at the last year, RDHL shows a very strong growth in Revenue. The Revenue has grown by 23.17%.
  • Measured over the past years, RDHL shows a small growth in Revenue. The Revenue has been growing by 5.04% on average per year.
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%58.59%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • Based on estimates for the next years, RDHL will show a very strong growth in Revenue. The Revenue will grow by 45.22% on average per year.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RDHL Yearly Revenue VS EstimatesRDHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
RDHL Yearly EPS VS EstimatesRDHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K -2K -2.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RDHL. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RDHL Price Earnings VS Forward Price EarningsRDHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RDHL Per share dataRDHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for RDHL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

REDHILL BIOPHARMA LTD-SP ADR

NASDAQ:RDHL (1/13/2026, 8:00:01 PM)

1.24

-0.03 (-2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-16
Earnings (Next)N/A
Inst Owners0.51%
Inst Owner Change19.9%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.13M
Revenue(TTM)8.04M
Net Income(TTM)-8.27M
Analysts82.86
Price TargetN/A
Short Float %917.26%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.79
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS2.42
BVpS-1.32
TBVpS-2.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.31%
FCFM N/A
ROA(3y)4.28%
ROA(5y)-16.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.56%
GM growth 5Y-1.2%
F-Score4
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.25%
Cap/Sales 0.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.42
Altman-Z -34.57
F-Score4
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)1.49%
Cap/Depr(5y)123.93%
Cap/Sales(3y)0.2%
Cap/Sales(5y)16.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)23.17%
Revenue growth 3Y-54.57%
Revenue growth 5Y5.04%
Sales Q2Q%58.59%
Revenue Next Year82.69%
Revenue Next 2Y55.97%
Revenue Next 3Y45.22%
Revenue Next 5YN/A
EBIT growth 1Y-215.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y68.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.74%
OCF growth 3YN/A
OCF growth 5YN/A

REDHILL BIOPHARMA LTD-SP ADR / RDHL FAQ

What is the fundamental rating for RDHL stock?

ChartMill assigns a fundamental rating of 1 / 10 to RDHL.


What is the valuation status of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?

ChartMill assigns a valuation rating of 0 / 10 to REDHILL BIOPHARMA LTD-SP ADR (RDHL). This can be considered as Overvalued.


How profitable is REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?

REDHILL BIOPHARMA LTD-SP ADR (RDHL) has a profitability rating of 1 / 10.


What is the financial health of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?

The financial health rating of REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 0 / 10.